Yep, agreed. If you look at companies like Nebula Genomics [1] (disclosure: I'm a founder) or Dante Labs [2], they're doing whole genome sequencing for comparable prices. I'm not sure why we aren't seeing a more prevalent shift to next-gen seqencing. [1] https://nebula.org [2] https://dantelabs.com